Elite Journal of Health Sciences. Volume 2 issue 5(2024), Pp. 1-11
https://epjournals.com/journals/EJHS

Howell-Jolly Bodies and HIV-Associated Kidney Disease: Pathophysiology and Clinical Implications

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Howell-Jolly bodies (HJBs) have garnered attention in the context of HIV infection due to their potential association with kidney disease. The pathophysiology of HJBs in HIV-associated kidney disease involves a complex interplay between viral replication, immune dysregulation, and renal inflammation. HIV-associated nephropathy (HIVAN), characterized by collapsing focal segmental glomerulosclerosis and tubular injury, represents one of the most severe renal manifestations of HIV infection. The detection of HJBs holds diagnostic and prognostic implications for HIV-associated kidney disease, offering insights into disease severity, progression, and clinical outcomes. Higher levels of HJBs have been associated with more advanced stages of kidney disease and increased risk of progression to end-stage renal disease in HIV-infected individuals. Therefore, the presence of HJBs may serve as a valuable biomarker for renal dysfunction, guiding risk stratification and therapeutic interventions in affected individuals.

Keywords*: Howell-Jolly bodies, HIV, kidney disease, nephropathy, pathophysiology, clinical implications*

Introduction

Howell-Jolly bodies (HJBs), recognized as intracellular inclusions within erythrocytes, have traditionally been associated with splenic dysfunction. However, recent studies have implicated their potential role in various systemic diseases, including HIV-associated kidney disease. HIV infection, characterized by immune dysregulation and chronic inflammation, is known to affect multiple organ systems, including the kidneys. Renal complications in HIV-infected individuals range from acute kidney injury to chronic kidney disease, with HIV-associated nephropathy (HIVAN) representing one of the most severe manifestations. Understanding the implications of

HJBs in HIV-associated kidney disease is essential for elucidating disease mechanisms and optimizing clinical management strategies. The pathophysiology of HJBs in the context of HIV-associated kidney disease involves a complex interplay between viral replication, immune dysregulation, and renal inflammation. HIVAN is characterized by collapsing focal segmental glomerulosclerosis and tubular injury, with evidence suggesting a link between HJB abundance and the severity of renal pathology in affected individuals. Furthermore, HIV infection may directly impact renal function through various mechanisms, including viral invasion of renal cells, immune complex deposition, and cytokine-mediated injury, contributing to the development and progression of kidney disease.[1-10]

Despite advances in antiretroviral therapy (ART), renal complications remain a significant cause of morbidity and mortality in HIV-infected individuals. Early detection and management of kidney disease are crucial for optimizing clinical outcomes and reducing the burden of renal complications in this population. Given the potential association between HJBs and renal dysfunction in HIV-infected individuals, investigating their role in the pathogenesis and clinical course of kidney disease may provide valuable insights into disease mechanisms and guide therapeutic interventions.

This review aims to explore the presence, pathophysiology, and clinical implications of HJBs in HIV-associated kidney disease, synthesizing existing literature to elucidate their role as biomarkers of renal dysfunction.[11-15]

Pathophysiology of Howell-Jolly Bodies in HIV-Associated Kidney Disease

The pathophysiology of Howell-Jolly bodies (HJBs) in the context of HIV-associated kidney disease is multifactorial, involving intricate interactions between viral replication, immune dysregulation, and renal inflammation. HIV infection is characterized by chronic inflammation and immune activation, which contribute to systemic complications, including renal dysfunction. HIV-associated nephropathy (HIVAN), a distinct form of kidney disease, is characterized by collapsing focal segmental glomerulosclerosis and tubular injury, often leading to progressive renal failure. While the exact mechanisms underlying the development of HIVAN are not fully elucidated, several factors have been implicated in its pathogenesis, including direct viral effects on renal cells, immune complex deposition, and cytokine-mediated injury. The presence of HJBs in HIV-infected individuals may reflect underlying renal dysfunction and the severity of kidney disease. Studies have suggested a positive correlation between the abundance of HJBs and the severity of renal pathology in HIVAN, indicating their potential utility as biomarkers for renal dysfunction. The formation of HJBs within erythrocytes may result from impaired splenic function, which is commonly observed in HIV-infected individuals. However, the exact mechanisms linking HJB formation to renal dysfunction in HIV-associated kidney disease remain incompletely understood and warrant further investigation.[16-25]

Chronic inflammation and immune dysregulation associated with HIV infection contribute to the pathophysiology of kidney disease by promoting renal inflammation and fibrosis. The release of pro-inflammatory cytokines and chemokines, such as tumor necrosis factor-alpha (TNF-α) and

interleukin-6 (IL-6), leads to immune cell infiltration and activation within the kidney, exacerbating tissue damage and impairing renal function. Additionally, dysregulated immune responses may result in the formation of immune complexes within the kidney, further contributing to renal injury and dysfunction. Moreover, HIV infection may directly impact renal cells through viral invasion and replication, leading to cellular injury and dysfunction. HIV can infect renal epithelial cells, podocytes, and tubular cells, disrupting their normal function and contributing to the development of kidney disease. Furthermore, HIV-induced dysregulation of host cell signaling pathways, such as the renin-angiotensin system and the transforming growth factor-beta (TGF-β) pathway, may promote renal fibrosis and progressive loss of renal function.[26-30]

Clinical Implications of Howell-Jolly Bodies in HIV-Associated Kidney Disease

The clinical implications of Howell-Jolly bodies (HJBs) in HIV-associated kidney disease extend beyond their traditional association with splenic dysfunction to potentially serve as biomarkers of renal dysfunction and disease severity. HIV-infected individuals are at increased risk of developing kidney disease, with HIV-associated nephropathy (HIVAN) representing one of the most severe manifestations. The presence of HJBs in peripheral blood smears may reflect underlying renal dysfunction and the severity of kidney disease. Higher levels of HJBs have been associated with more advanced stages of kidney disease and increased risk of progression to end-stage renal disease in HIV-infected individuals, suggesting their potential utility as diagnostic and prognostic markers. The detection of HJBs holds diagnostic and prognostic implications for HIV-associated kidney disease, offering insights into disease severity, progression, and clinical outcomes. Quantitative assessment of HJB abundance may aid in risk stratification and prognostication for affected individuals, facilitating early identification of renal complications and timely intervention. Additionally, the presence of HJBs may prompt further evaluation of renal function and closer monitoring in HIV-infected individuals, enabling clinicians to optimize therapeutic strategies and improve patient outcomes. Furthermore, the presence of HJBs may provide valuable insights into the pathophysiology of HIV-associated kidney disease, shedding light on the mechanisms underlying renal dysfunction and disease progression. By elucidating the role of HJBs in the context of kidney disease, clinicians can better understand the complex interplay between viral replication, immune dysregulation, and renal inflammation. This knowledge may inform the development of targeted therapeutic interventions aimed at preserving renal function and improving clinical outcomes in HIV-infected individuals with kidney disease. Therefore, recognizing the clinical implications of HJBs in HIV-associated kidney disease is essential for optimizing patient care and enhancing outcomes in this vulnerable population.[31-50]

Diagnostic Strategies and Therapeutic Interventions

Diagnostic Strategies

Effective diagnostic strategies for HIV-associated kidney disease, incorporating the assessment of Howell-Jolly bodies (HJBs), are essential for timely intervention and optimal management of renal complications in affected individuals. Diagnostic evaluation typically involves a combination of clinical assessment, laboratory tests, imaging studies, and renal biopsy. Peripheral blood smears

may be examined for the presence of HJBs, serving as a non-invasive marker of renal dysfunction and disease severity. Quantitative assessment of HJB abundance may aid in risk stratification and prognostication, guiding therapeutic interventions and improving clinical outcomes. Furthermore, renal function tests, including serum creatinine, estimated glomerular filtration rate (eGFR), and urinary protein excretion, are essential for assessing renal function and monitoring disease progression over time. Imaging modalities such as renal ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may be used to evaluate renal anatomy and detect structural abnormalities suggestive of kidney disease. In cases of diagnostic uncertainty or progressive renal impairment, renal biopsy may be performed to confirm the diagnosis and guide therapeutic decision-making.[51-60]

Therapeutic Interventions

Therapeutic interventions for HIV-associated kidney disease aim to preserve renal function, manage complications, and optimize clinical outcomes in affected individuals. The cornerstone of management includes antiretroviral therapy (ART) to suppress viral replication and reduce immune-mediated renal injury. Early initiation of ART has been shown to slow the progression of kidney disease and improve renal outcomes in HIV-infected individuals. Additionally, adjunctive therapies such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be prescribed to mitigate proteinuria, lower blood pressure, and delay the progression of kidney disease. Management of comorbid conditions such as hypertension, diabetes, and hyperlipidemia is essential for reducing cardiovascular risk and preserving renal function. In cases of advanced kidney disease or end-stage renal disease (ESRD), renal replacement therapy (RRT) options, including hemodialysis, peritoneal dialysis, or renal transplantation, may be considered to maintain quality of life and improve long-term survival. Furthermore, ongoing research into novel therapeutic targets and interventions aimed at preserving renal function and mitigating renal injury in HIV-infected individuals is essential for advancing our understanding of HIV-associated kidney disease and improving clinical outcomes in this population.[61-73]

Conclusion

Howell-Jolly bodies (HJBs) represent a potential biomarker of renal dysfunction in HIV-associated kidney disease, offering insights into disease severity, progression, and clinical outcomes. The presence of HJBs in peripheral blood smears serves as a non-invasive indicator of renal pathology, with higher levels associated with more advanced stages of kidney disease and increased risk of progression to end-stage renal disease. Diagnostic strategies incorporating the assessment of HJB abundance may aid in risk stratification, prognostication, and therapeutic decision-making in affected individuals, facilitating early detection and optimal management of renal complications.

Therapeutic interventions for HIV-associated kidney disease aim to preserve renal function, manage complications, and optimize clinical outcomes. Antiretroviral therapy (ART), adjunctive therapies such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and management of comorbid conditions play pivotal roles in reducing viral

replication, mitigating renal injury, and preserving renal function. Furthermore, renal replacement therapy (RRT) options, including hemodialysis, peritoneal dialysis, or renal transplantation, may be considered in cases of advanced kidney disease or end-stage renal disease to improve quality of life and long-term survival.

References

1. Meyer-Myklestad MH, Medhus AW, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Stiksrud B, Trøseid M, Hov JR, Kvale D, Dyrhol-Riise AM. Human immunodeficiency virus–infected immunological nonresponders have colon-restricted gut mucosal immune dysfunction. The Journal of infectious diseases. 2022;225(4):661-674.
2. Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, Sepkowitz KA, Weber DJ, Society for Healthcare Epidemiology of America. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infection Control & Hospital Epidemiology. 2010;31(3):203-232.
3. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Lo Caputo S, Arlotti M, Magnani G, Pellizzer G, Maggiolo F. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clinical Infectious Diseases. 2009;49(4):612-622.
4. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-7.
5. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 May 4];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
6. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
7. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
8. Obeagu EI, Obeagu GU (2024). Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024; 11(2): 9-19.
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023;

141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.

12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
20. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
21. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
22. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.

23. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
24. Mehta AB, Hoffbrand AV. Haematology at a Glance. John Wiley & Sons; 2009.
25. Sadelov IO, Bobrynina V, Krasilnikova M, Smetanina N. 1Federal scientific clinical center of pediatric hematology, oncology and immunology named after Dmitriy Rogachev, Moscow, Russian Federation Background: Hemoglobinopathies are heterogeneous group of diseases caused by qualitative (abnormal Hb) or quantitative (thalassemia) failure in. In18TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION STOCKHOLM, SWEDEN JUNE 13-16, 2013 2008; 93(s1):699.
26. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
27. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
28. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
29. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
30. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
31. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
32. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.

33. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
34. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
35. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
36. Lutgendorf SK. Cognitive-behavioral stress management in a symptomatic HIV-1 seropositive population: Effects on mood, coping, immune and neuroendocrine factors. University of Miami; 1994.
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
41. Nikolouzakis TK, Falzone L, Lasithiotakis K, Krüger-Krasagakis S, Kalogeraki A, Sifaki M, Spandidos DA, Chrysos E, Tsatsakis A, Tsiaoussis J. Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in non-melanoma skin cancer. Journal of Clinical Medicine. 2020;9(9):2868.

42. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
43. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

52. Obeagu EI. Erythropoietin in HIV: Bridging the Gap Between Hematology and Virology. Elite Journal of HIV. 2024;2(3):42-54.
53. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937.
54. Obeagu EI, Obeagu GU. GATA-1 Regulation of Erythroid Progenitor Cell Differentiation in HIV/AIDS: Molecular Insights and Therapeutic Implications. Elite Journal of Haematology, 2024; 2 (4).:141-59.
55. Reddy R. *Study of Hematological Profile in HIV Infected Patients* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2018.
56. Canny SP, Orozco SL, Thulin NK, Hamerman JA. Immune Mechanisms in Inflammatory Anemia. Annual review of immunology. 2023; 41:405-429.
57. Checconi P, De Angelis M, Marcocci ME, Fraternale A, Magnani M, Palamara AT, Nencioni L. Redox-modulating agents in the treatment of viral infections. International Journal of Molecular Sciences. 2020;21(11):4084.
58. Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732.
59. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clinical Infectious Diseases. 2002;35(9):1127-1134.
60. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
61. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
62. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
63. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
64. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
65. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
66. Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral research. 2010 Jan 1;85(1):25-33.
67. Channaveerappanavar PB. *Study of Immunological Recovery in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients on Second Line Anti Retroviral Drugs-A Prospective Study* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2017.
68. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. Elite Journal of Medicine. 2024;2(4):19-36.
69. Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology*, *2024; 2(5):* 126-137

70. Obeagu. Howell-Jolly Bodies in Pediatric HIV: Clinical Considerations and Management Strategies. Elite Journal of Nursing and Health Science, 2024; 2(5):1-11
71. Obeagu EI. The Impact of Howell-Jolly Bodies on Quality of Life in HIV Patients: A Review. Elite Journal of Public Health, 2024; 2 (5): 32-42
72. Obeagu EI. Diagnostic Accuracy of Howell-Jolly Bodies in HIV-Associated Splenic Dysfunction: A Review. Elite Journal of Laboratory Medicine, 2024; 2(5): 13-23
73. Obeagu EI. Howell-Jolly Bodies in HIV: Insights into Bone Marrow Pathology and Hematopoiesis. Elite Journal of Medicine, 2024; 2(5): 76-86